The mutated KRAS subgroup of patients had, as expected, a higher percentage of adenocarcinoma histology (85.0% compared to 65.8% for mutated and wild-type respectively) and a lower prevalence of never smoker patients (6.7% compared to 22.5% for mutated and wild-type respectively). This evidence concerns the gene KRAS and adenocarcinoma.